An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

Walter Fiedler,[1] Pau Montesinos,[2,3] Christoph Schliemann,[4] Jan Middeke,[5] Sumithira Vasu,[6] Christian W. Scholz,[7] Jordi Esteve,[8] Shoubhik Mondal,[9] Björn Rüter,[10] Ute Burkard,[10] Annika Osswald[10]
and William Blum[11]
[1]Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; [2]Hospital Universitari i Politècnic La Fe, Valencia, Spain; [3]CIBERONC, Instituto Carlos III, Madrid, Spain; [4]Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany; [5]Uniklinikum Dresden, Dresden, Germany; [6]Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; [7]Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin, Germany; [8]Hematology Department, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain; [9]Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; [10]Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, Germany and [11]Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.

Correspondence:
W. BLUM - william.g.blum@emory.edu

https://doi.org/10.3324/haematol.2022.281128

Supplementary Table S1. Comparison of Cmax in cycle 1, day 9 and day 23, for all dose groups.

Plasma concentrations		
Dose [mg]	**Day 9, 6 h [ng/mL]**	**Day 23, 6 h [ng/mL]**
20	1790	4390
40	6400	7210
80	14,700	22,300

Supplementary Figure S1. Percentage CD33+ blasts (A), CD3-/CD16+ NK cells (B) and CD3-/CD16+/CD69+ activated NK cells (C) in the peripheral blood of individual patients treated with treated with BI 836858 80 mg.

A)



B)



C)



NK: natural killer.